ClinicalTrials.gg
TerminatedNCT00427583Updated Aug 7, 2012

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

A Phase 2/3 interventional study of imatinib mesylate in Malignant Peripheral Nerve Sheath Tumors, sponsored by Novartis Pharmaceuticals. Terminated at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
stopped due to slow recruitment and no effect

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors

02

Conditions studied

  • Malignant Peripheral Nerve Sheath Tumors

Keywords

  • Malignant,
  • peripheral,
  • nerve sheath tumors,
  • MPNST,
  • neurofibromatosis,
  • NF1,
  • Imatinib mesylate
03

In context

Neurofibrosarcoma

98 studies on the registry are indexed under Neurofibrosarcoma; 23 are open to participants now.

This study's enrollment of 11 is below the median of 46 across 84 interventional studies indexed under Neurofibrosarcoma.

Browse Neurofibrosarcoma studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥18 years of age
  • documented diagnosis of malignant MPNST
  • Unresectable local MPNST or MPNST and therefore incurable with any conventional multimodality approach of at least 6 months.

Exclusion criteria

Exclusion criteria:

  • Patient has received any other agents within 28 days of first day of study drug dosing.
  • Chemotherapy and or radiotherapy in between the last 6 weeks before study entry, surgery in between the last 14 days before study entry.
  • Female patients who are pregnant or breast feeding or women of child bearing potential who are not using a highly effective method of .
  • Known

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    STI571

    Drug: imatinib mesylate

Interventions

06

What researchers measure

Primary outcomes

  1. Response rate assessed by a Tumor MRI scan every 6 weeks or if clinically indicated.

    Time frame: Every 36 weeks

Secondary outcomes

  1. Time to progression assessed by an MRI scan.

    Time frame: Every 36 weeks

  2. Overall survival

    Time frame: Every 36 weeks

  3. Safety and tolerability assessed by abnormal lab values (hematology, biochemistry, urinalysis), by physical examination and vital signs

    Time frame: Every 36 weeks

07

Study locations

2 sites
  • Novartis Investigative Site
    Berlin, Germany
  • Novartis Investigative Site
    Hamburg, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006 and a primary completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2007
First posted
Jan 29, 2007
Start
May 2006
Primary completionActual
Apr 2009
Last update
Aug 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00427583
Responsible party
Sponsor
First posted
Jan 29, 2007
Start date
May 2006
Primary completion
Apr 2009
Last update
Aug 7, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmeceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion